Zacks: Brokerages Expect Spero Therapeutics Inc (SPRO) Will Announce Earnings of -$0.76 Per Share

Share on StockTwits

Analysts forecast that Spero Therapeutics Inc (NASDAQ:SPRO) will report earnings of ($0.76) per share for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Spero Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.61) and the lowest estimate coming in at ($0.96). Spero Therapeutics reported earnings of ($1.59) per share in the same quarter last year, which would indicate a positive year over year growth rate of 52.2%. The firm is expected to issue its next earnings results on Monday, April 1st.

According to Zacks, analysts expect that Spero Therapeutics will report full year earnings of ($2.81) per share for the current fiscal year, with EPS estimates ranging from ($3.01) to ($2.62). For the next fiscal year, analysts anticipate that the company will report earnings of ($3.35) per share, with EPS estimates ranging from ($4.08) to ($2.59). Zacks’ EPS averages are an average based on a survey of analysts that follow Spero Therapeutics.

Spero Therapeutics (NASDAQ:SPRO) last announced its quarterly earnings results on Thursday, November 8th. The company reported ($0.60) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.64) by $0.04. Spero Therapeutics had a negative return on equity of 52.22% and a negative net margin of 1,402.91%. The firm had revenue of $0.66 million for the quarter, compared to analysts’ expectations of $0.66 million.

Several equities research analysts have recently weighed in on the company. Cantor Fitzgerald reiterated a “buy” rating and set a $27.00 price target on shares of Spero Therapeutics in a research report on Thursday, August 9th. Oppenheimer set a $30.00 price target on Spero Therapeutics and gave the company a “buy” rating in a research report on Friday, August 10th. Zacks Investment Research upgraded Spero Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a research report on Wednesday, August 15th. Finally, Bank of America cut shares of Spero Therapeutics from a “neutral” rating to an “underperform” rating and decreased their price objective for the stock from $19.00 to $9.00 in a research report on Tuesday, October 16th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $20.70.

Shares of SPRO traded down $0.15 during midday trading on Thursday, hitting $7.02. 6,520 shares of the company traded hands, compared to its average volume of 54,306. Spero Therapeutics has a one year low of $6.98 and a one year high of $19.00. The stock has a market cap of $123.37 million and a PE ratio of -0.39.

Several hedge funds have recently bought and sold shares of the stock. PNC Financial Services Group Inc. bought a new position in shares of Spero Therapeutics in the second quarter worth approximately $146,000. Bank of New York Mellon Corp increased its position in shares of Spero Therapeutics by 73.9% in the second quarter. Bank of New York Mellon Corp now owns 24,689 shares of the company’s stock worth $363,000 after purchasing an additional 10,490 shares during the last quarter. Millennium Management LLC bought a new position in shares of Spero Therapeutics in the first quarter worth approximately $163,000. Renaissance Technologies LLC bought a new position in shares of Spero Therapeutics in the third quarter worth approximately $126,000. Finally, Highland Capital Management LP bought a new position in shares of Spero Therapeutics in the third quarter worth approximately $210,000. Institutional investors own 52.93% of the company’s stock.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; and SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting.

Featured Story: SEC Filing

Get a free copy of the Zacks research report on Spero Therapeutics (SPRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Spero Therapeutics (NASDAQ:SPRO)

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Windsor Group LTD Has $571,000 Stake in BlackRock, Inc.
Windsor Group LTD Has $571,000 Stake in BlackRock, Inc.
Head to Head Contrast: TPG Specialty Lending  & OHA Investment
Head to Head Contrast: TPG Specialty Lending & OHA Investment
Tyme Technologies Inc  Expected to Announce Earnings of -$0.08 Per Share
Tyme Technologies Inc Expected to Announce Earnings of -$0.08 Per Share
Fortis Inc  Receives Average Recommendation of “Hold” from Analysts
Fortis Inc Receives Average Recommendation of “Hold” from Analysts
Oxford Industries Inc  Given Average Recommendation of “Hold” by Brokerages
Oxford Industries Inc Given Average Recommendation of “Hold” by Brokerages
Blue Fin Capital Inc. Sells 250 Shares of Connecticut Water Service Inc
Blue Fin Capital Inc. Sells 250 Shares of Connecticut Water Service Inc


Leave a Reply

 
© 2006-2019 Zolmax.